Yeil Kim
Research Subjects
Yeil Kim has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Andreas P. Pintado-Urbanc
1 shared publication- Aurora A. Miranda
Department of Chemistry, University of Illinois Urbana-Champaign , 600 South Mathews Avenue , Urbana , IL 61801 , USA
1 shared publication - Courtney L. Brown
Yale Combined Program in the Biological and Biomedical Sciences, Yale University
1 shared publication - Jimin Wang
Yale University
1 shared publication Joshua T. Young
1 shared publication- Matthew D. Simon
Yale University
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by Elsevier in Journal of Biological Chemistry
The histone deacetylase inhibitor romidepsin increases cellular acetyl-methyllysine
- 17 November 2026
- Published by Elsevier in Journal of Biological Chemistry
Open AccessThe histone deacetylase inhibitor romidepsin increases cellular acetyl-methyllysine
- 11 February 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (5) , 517-520
Computational Evolution of Anti-PD-1 Antibodies Induces Structural Refolding for High-Affinity Interactions
Checkpoint inhibitors targeting the PD-1/PD-L1 axis are key immunotherapies, but the dynamic and flexible nature of PD-1 complicates rational antibody engineering. Here, we use computational saturation mutagenesis, AlphaFold prediction, and molecular dynamics (MD) simulations to evolve pembrolizumab variants with suitable binding. Seven engineered antibodies form additional salt bridges and hydrophobic contacts via refolding of both the antibody and the PD-1 interface. One variant, m7p.5, displays improved biphasic kinetics and high-affinity binding (KD,apparent = 62 pM). Structural changes include an α-helix to loop transition in the antibody heavy chain and a 4.6-Å Cα shift of a PD-1 loop. These results show that computational evolution can access binding modes inaccessible to traditional rigid structural design, enabling high-affinity antibodies for flexible targets. It is demonstrated that our integrated computational approaches including MD simulations can generate new picomolar high-affinity antibodies targeting specific epitopes of proteins that may be intrinsically flexible and are difficult to target with reasonable computational cost, which would be far less than an experimental cost for finding new antibodies with equivalent binding affinities. This study provides a new tool that can be combined with other artificial-intelligence-based antibody generation against PD-1 from the existing anti-PD-1 antibody library with broad applications in protein-protein interactions.
- 11 February 2026
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 65 (5) , 517-520
Computational Evolution of Anti-PD-1 Antibodies Induces Structural Refolding for High-Affinity Interactions
Checkpoint inhibitors targeting the PD-1/PD-L1 axis are key immunotherapies, but the dynamic and flexible nature of PD-1 complicates rational antibody engineering. Here, we use computational saturation mutagenesis, AlphaFold prediction, and molecular dynamics (MD) simulations to evolve pembrolizumab variants with suitable binding. Seven engineered antibodies form additional salt bridges and hydrophobic contacts via refolding of both the antibody and the PD-1 interface. One variant, m7p.5, displays improved biphasic kinetics and high-affinity binding (KD,apparent = 62 pM). Structural changes include an α-helix to loop transition in the antibody heavy chain and a 4.6-Å Cα shift of a PD-1 loop. These results show that computational evolution can access binding modes inaccessible to traditional rigid structural design, enabling high-affinity antibodies for flexible targets. It is demonstrated that our integrated computational approaches including MD simulations can generate new picomolar high-affinity antibodies targeting specific epitopes of proteins that may be intrinsically flexible and are difficult to target with reasonable computational cost, which would be far less than an experimental cost for finding new antibodies with equivalent binding affinities. This study provides a new tool that can be combined with other artificial-intelligence-based antibody generation against PD-1 from the existing anti-PD-1 antibody library with broad applications in protein-protein interactions.